SCHEMBL1010905

SCHEMBL1010905

OCc1cccc(Oc2ncc(Br)cn2)c1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 4/20 0.42
NR1H3 Q13133 4/20 0.42
GPBAR1 Q8TDU6 1/20 0.42
CYSLTR1 Q9Y271 1/20 0.42
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAOB P27338 2/20 0.39
F10 P00742 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HTT P42858 1/20 0.38
TTR P02766 1/20 0.37
KDR P35968 1/20 0.37
FFAR1 O14842 1/20 0.37
CYP4F2 P78329 1/20 0.36
CYP4A11 Q02928 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4188638 0.93 GPBAR1 (0.40) NR1H2NR1H3GPBAR1CYSLTR1TSHR
SCHEMBL27209661 0.84 NR1H2 (0.47) NR1H2NR1H3GPBAR1CYSLTR1TSHR
SCHEMBL1013138 0.84 MEN1 (0.40) TSHRSMN1; SMN2MAOBMEN1KMT2A
SCHEMBL3288907 0.83 MEN1 (0.53) NR1H2NR1H3GPBAR1CYSLTR1TSHR
SCHEMBL27209670 0.82 ALDH1A1 (0.41) NR1H2NR1H3GPBAR1CYSLTR1TSHR
SCHEMBL11478458 0.78 MAOB (0.53) TSHRSMN1; SMN2MAOBTTR
SCHEMBL9560397 0.77 LTA4H (0.53) TSHRSMN1; SMN2MAOBMEN1KMT2A
SCHEMBL27209663 0.76 LOXL2 (0.44) NR1H2NR1H3GPBAR1CYSLTR1TSHR
SCHEMBL24156258 0.76 MEN1 (0.61) SMN1; SMN2MAOBMEN1KMT2AHTT
SCHEMBL22405016 0.76 RAB9A (0.51) SMN1; SMN2MAOBMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044052-B2 Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis PFIZER INC. (US) 2011-10-25 US disclosed
EP-2076508-B1 BIARYL ETHER UREA COMPOUNDS PFIZER PROD INC (US) 2011-01-05 EP disclosed
EP-2076508-A2 BIARYL ETHER UREA COMPOUNDS Pfizer Products Inc. (US) 2009-07-08 EP disclosed
US-20080261941-A1 Biaryl Ether Urea Compounds Jazz Pharmaceuticals Therapeutics, Inc. 2008-10-23 US disclosed
WO-2008047229-A2 BIARYL ETHER UREA COMPOUNDS PFIZER PRODUCTS INC. (US) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261941-A1 Biaryl Ether Urea Compounds FAAH, FAAH2, LIPC NR1H2 52/4885NR1H3 44/4885GPBAR1 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.